In AD, tau phosphorylation and truncation translate from the brain into cerebrospinal fluid (CSF), where increased levels of both total tau (t-tau) and phosphorylated forms (p-tau) have been used as specific biomarkers of neurodegeneration and AD, respectively [8, 24, 25]. Here, MAPT is linked to Alzheimer disease.